Phase 2 N=115 S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
Leukemia
Primary: Complete Remission (CR) Rate (Including CR With Incomplete Recovery) — 27; 14; 14 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=276 Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Area Under the Concentration-Time Curve From Time 0 to 336 Hours (AUC0-336) Post First Dose — 49000; 49000; 51400 ug*h/ml
Phase 2 N=18 Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies
Developmental and/or Epileptic Encephalopathies
Primary: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE), as Reported by the Participants or Participant's Caregivers or Observed by the…
Phase 2 N=60 Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria
Hyperuricemia · Albuminuria · Type 2 Diabetes
Primary: Urinary Albumin to Creatinine Ratio (UACR) — -48.65; -15.31 Precent change
Phase 2 N=45 Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
Idiopathic Thrombocytopenic Purpura
Primary: Number of Participants With Adverse Events — 4; 4; 4; 4 Participants
Phase 2 N=66 Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia
Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities — 0; 0 Participants
Phase 2 N=10 Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
Locally Advanced Malignant Neoplasm · Breast Cancer
Primary: Mean Adherence to Propranolol — 96 Percentage of propanolol adherence
Phase 2 N=66 A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness
Excessive Sleepiness · Parkinson Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Early Discontinuation — 1; 2; 0; 0 Participants
Phase 2 N=60 The Role of Oral Glutathione on Growth Parameters in Children With Cystic Fibrosis
Cystic Fibrosis
Primary: Change in Weight-for-age Z-score — -0.018; 0.045 Z-score — p=0.2521
Phase 2 N=19 Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab
Advanced Malignant Neoplasm · Dermatologic Complication
Primary: Number of Patients Reporting a Grade 2+ Adverse Event Attributed to Spironolactone (Study I) — 0; 0 Participants
Phase 2 N=218 A Study of LY2951742 in Participants With Migraine
Migraine Headache
Primary: Mean Change From Baseline in the Number of Migraine Headache Days in the Last 28-day Period of the 12-week Treatment Phase — -4.2; -3.0 Migraine headache days
Phase 2 N=14 High and Low Dose Carbidopa Treatment of Parkinson's Disease
Parkinson's Disease
Primary: Area Under the Curve (AUC) of Tapping Speed — 141; 141; 145; 201 (taps/min)*(hours)
Phase 2 N=22 Fecal Microbiota Transplantation for the Treatment of Obesity
Obesity
Primary: Adverse Event Frequency — 11; 11; 1; 0 Participants
Phase 2 N=23 A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure
Non-Ischemic Heart Failure
Primary: Safety Will be Evaluated by Number of AE — 38; 35; 1; 1 number of events
Phase 2 N=113 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)
MSI Positive Colorectal Cancer · MSI Negative Colorectal Cancer · MSI Positive Non-Colorectal Cancers
Primary: Immune-related Progression Free Survival (irPFS) at 20 Weeks in MSI Positive and Negative Colorectal Adenocarcinoma Participants Using Immune Related Response Criteria…